Not yet taking people in Lengyelország1. fázis
Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma; MEDWAY
Key facts
- Where
- Warsaw, LengyelországSee the site
- Phase
- 1. fázis
Where in Lengyelország
- Instytut Pomnik Centrum Zdrowia DzieckaWarsaw, LengyelországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instytut Pomnik Centrum Zdrowia Dziecka
- Trial code
- EU 2025-524031-39-00
- Record updated
- 2026. október 28.
- Original description
1. To evaluate the safety and toxicity of RVU120 as a single agent and combined with everolimus when administered to children with recurrent or progressive G3 or G4 medulloblastoma 2. To determine the MTD and/or RP2D of RVU120 as a single agent and in combination with everolimus in children with recurrent or progressive G3 or G4 medulloblastoma.Read full original descriptionShow less
1. To evaluate the safety and toxicity of RVU120 as a single agent and combined with everolimus when administered to children with recurrent or progressive G3 or G4 medulloblastoma 2. To determine the MTD and/or RP2D of RVU120 as a single agent and in combination with everolimus in children with recurrent or progressive G3 or G4 medulloblastoma.